Cms posts preliminary payment determination for new category i cpt code covering use of ogm for constitutional genetic disorders

San diego, sept. 15, 2025 (globe newswire) -- bionano laboratories, a wholly-owned subsidiary of bionano genomics, inc. (nasdaq: bngo) offering clia-certified laboratory developed tests (ldts) based on optical genome mapping (ogm), today announced that centers for medicare & medicaid services (cms) posted the preliminary payment determination for the category i current procedural terminology (cpt®) code for use of ogm in cytogenomic genome-wide analysis to detect structural and copy number variations related to constitutional genetic disorders.
BNGO Ratings Summary
BNGO Quant Ranking